Assembly Biosciences’ (ASMB) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research note issued to investors on Tuesday, Benzinga reports.

Separately, Jefferies Financial Group upgraded Assembly Biosciences from a hold rating to a buy rating and raised their target price for the company from $2.00 to $35.00 in a research report on Friday, September 20th.

Assembly Biosciences Trading Up 1.4 %

Shares of ASMB stock opened at $15.55 on Tuesday. The business’s 50 day moving average is $15.52 and its two-hundred day moving average is $14.52. Assembly Biosciences has a 12-month low of $7.69 and a 12-month high of $20.04.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.96) by $0.98. The business had revenue of $8.53 million for the quarter, compared to analysts’ expectations of $5.96 million. On average, equities analysts predict that Assembly Biosciences will post -7.82 earnings per share for the current year.

Insider Buying and Selling

In other Assembly Biosciences news, major shareholder Alexander Schornstein bought 4,438 shares of the business’s stock in a transaction on Friday, July 5th. The stock was bought at an average price of $12.52 per share, with a total value of $55,563.76. Following the completion of the purchase, the insider now directly owns 693,113 shares in the company, valued at $8,677,774.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 5.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Assembly Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new stake in shares of Assembly Biosciences in the second quarter valued at $6,421,000. Renaissance Technologies LLC grew its stake in Assembly Biosciences by 39.2% during the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 15,451 shares in the last quarter. Finally, Acadian Asset Management LLC grew its stake in Assembly Biosciences by 131.0% during the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 7,690 shares in the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.